MAPT and early-onset autosomal dominant Alzheimer disease: The development of PET tracers for amyloid β and, more recently, tau tangles in the past 15 years has revolutionized clinical trials in Alzheimer’s disease—permitting, after a fashion, neuropathology to be performed longitudinally in living persons.